It seems that this facilitatory effect of high-dose losartan may be mediated by activation of the Ca2+ influx through L-type Ca2+ channels into adrenomedullary cells without inhibition of NO synthesis, which seems to be relevant to AT2 receptor blockade. It also suggests that high-dose ARBs ...
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial Angiotensin-receptor blockers (ARBs) are effective treatments for patients with heart failure, but the relation between dose and clinical outcomes has ...
The effect of angiotensin Ⅱ receptor antagonists on posttransplant erythrocytosis; 血管紧张素Ⅱ受体拮抗剂对肾移植后红细胞增多症的影响 2. Effect of Losartan on Postrenal Transplant Erythrocytosis; 氯沙坦治疗肾移植后红细胞增多症 3. Objective: To discuss the causes of secondary erythrocytosis and the...
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840–1848. Article CAS PubMed Google Scholar Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, ...
Our previous study has clearly identified that PGC-1α expression which was significantly downregulated in diabetic cardiomyopathy was significantly reversed by losartan (i.e., one kind of ARBs) [27]. Intriguingly, not only in our in vitro (i.e., cell model) but also in our in vivo (i....
Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan22; SHELL, Systolic Hypertension in the ELderLy28; STOP-2, Swedish Trial in Patients with Hypertension-217; Syst-China, Systolic Hypertension in China11; Syst-Eur, Systolic Hypertension in Europe10; TRANSCEND, Telmisartan Rand...
Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan22; SHELL, Systolic Hypertension in the ELderLy28; STOP-2, Swedish Trial in Patients with Hypertension-217; Syst-China, Systolic Hypertension in China11; Syst-Eur, Systolic Hypertension in Europe10; TRANSCEND, Telmisartan Rand...
(candesartan, losartan, valsartan, etc.), angiotensin converting enzyme inhibitors, calcium channel antagonists (amlodipine, cilnidipine, etc.), and α1 blockers; diabetes drugs or abnormal glucose tolerance stimulants such as α-glucosidase inhibitors (voglibose, acarbose, etc.), biguanide drugs, ...
Results The patient was shown to have a higher activity of CYP2C9 than any of the 190 healthy Swedish Caucasians used as controls. Conclusions Our finding of an ultrarapid metabolism of losartan and phenytoin may apply to other CYP2C9 substrates, where inhibition of CYP2C9 may cause severe...
- 《International Journal of Clinical Pharmacology & Therapeutics》 被引量: 57发表: 1994年 2011 - Review: Low-dose hydrochlorothiazide is not as effective as other antihypertensive drugs for reducing ambulatory BP in hypertension? HCTZ was compared with atenolol or losartan in 4 trials each; ...